►个人简介

工作职位：药物制剂教研室，副教授（特聘），硕士生导师

办公地址：青岛科技大学科技园北楼607（青岛市市北区郑州路53号）

招生专业：药学1007/1055

工作邮箱：gcl_cpu@126.com；guochuanlong@qust.edu.cn

2019年获中国科学院海洋研究所海洋生物学专业博士学位，2013年6月至2016年6月，任职于山东省眼科研究所。2019年7月–至今，任职于皇冠hg1088官方药物制剂教研室。主要从事新型抗肿瘤药物研制与开发、活性化合物筛选及作用机制研究。作为项目负责人，主持山东省自然科学基金2项，参与国家自然科学基金项目3项。近五年，发表SCI论文20余篇，其中第一作者发表SCI论文16篇，作为主要参与人授权国家发明专利7项。

►教学情况

体内药物分析：32课时，研究生，约20人。

细胞生物学：32学时，本科，约60人。

生物化学与分子生物学：60学时，本科，约60人。

►论文与专利

1、主要论文

[1]Chuanlong Guo, Yuzhen Hou, Xuemin Yu, Fan Zhang, Xiaochen Wu, Xianggen Wu and Lijun Wang. The ERK-MNK-eIF4F signaling pathway mediates TPDHT-induced A549 cell deathin vitroandin vivo.Food and Chemical Toxicology, 137 (2020) 111158.

[2]Chuanlong Guo, Fan Zhang, Xiaochen Wu, Xuemin Yu, Xianggen Wu, Dayong Shi and Lijun Wang. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activitiesin vitroandin vivo. International Journal of Biological Macromolecules, 150 (2020) 238–245.

[3] Lijun Wang, Shuhong Zhang, Xuemin Yu andChuanlong Guo*. Novel Poly(ADP-ribose) Polymerase‑1 Inhibitor DDHCB Inhibits Proliferation of BRCA Mutant Breast Cancer Cell In Vitro and In Vivo through a Synthetic Lethal Mechanism. Chem. Res. Toxicol. 2020, 33, 1874−1881.

[4] Jun Wang, Lijun Wang, Shuhong Zhang, Junting Fan, Hui Yang, Qiqi Li andChuanlong Guo*.Novel eIF4E/eIF4G protein-protein interaction inhibitors DDH-1 exhibits anti-cancer activity in vivo and in vitro. International Journal of Biological Macromolecules 160 (2020) 496–505.

[5]Chuanlong Guo¹, Lijun Wang¹, Xiuxue Li, Shuaiyu Wang, Xuemin Yu, Kuo Xu, Yue Zhao, Jiao Luo, Xiangqian Li, Bo Jiang, Dayong Shi. Discovery of novel bromophenol – thiosemicarbazone hybrids as potent selectve inhibitors of poly(ADPribose) polymerase-1 (PARP-1) for use in cancer. Journal of Medicinal Chemistry. 2019, 62, 3051−3067.

[6] Lijun Wang¹,Chuanlong Guo¹,Xiuxue Li, Xuemin Yu, Xiangqian Li, Kuo Xu, Bo Jiang, Xiaoling Jia, Chao Li, Dayong Shi.Design, synthesis and biological evaluation of bromophenol-thiazolylhydrazone hybrids inhibiting the interaction of translation initiation factors eIF4E/eIF4G as multifunctional agents for cancer treatment. European Journal of Medicinal Chemistry. 2019, 177:153-170.

[7]Chuan-Long Guo¹Li-Jun Wang¹, Yue Zhao, Hua Liu, Xiang-Qian Li，Bo Jiang, Jiao Luo, Shu-Ju Guo, Ning Wu, Da-Yong Shi. A Novel Bromophenol Derivative BOS-102 Induces Cell Cycle Arrest and Apoptosis in Human A549 Lung Cancer Cells via ROS-Mediated PI3K/Akt and the MAPK Signaling Pathway. Mar. Drugs. 2018, 16, 43.

[8]Kuo Xu¹,Chuanlong Guo¹, Jie Meng, Haiying Tian, Shuju Guo, Dayong Shi.Discovery of Natural Dimeric Naphthopyrones as Potential Cytotoxic Agents Through ROS-mediated Apoptotic Pathway. Mar. Drugs. 2019, 17, 207

[9]Li-Jun Wang¹,Chuan-Long Guo¹,Xiang-Qian Li, Shuai-Yu Wang, Bo Jiang, Yue Zhao, Jiao Luo, Kuo Xu, Hua Liu, Shu-Ju Guo, Ning Wu, Da-Yong Shi. Discovery of Novel Bromophenol Hybrids as Potential Anticancer Agents through the Ros-Mediated Apoptotic Pathway: Design, Synthesis and Biological Evaluation. Mar. Drugs. 2017, 15, 34.

[10]Chuanlong Guo¹, Mengshuang Li^1,Xia Qi, Guiming Lin, Fenghua Cui, Fengjie Li, Xianggen Wu. Intranasal delivery of nanomicelle curcumin promotes corneal epithelial wound healing in streptozotocin-induced diabetic mice. Sci Rep. 2016, 6: 29753.

[11]Chuanlong Guo, Fenghua Cui, Mengshuang Li, Fengjie Li, Xianggen Wu. Enhanced corneal permeation of coumarin-6 using nanoliposomes containing dipotassium glycyrrhizinate:in vitromechanism andin vivopermeation evaluation. RSC Adv. 2015, 5, 75636.

[12]Chuanlong Guo¹, Yan Zhang¹, Zhao Yang, Mengshuang Li, Fengjie Li, Fenghua Cui, Ting Liu, Weiyun Shi, Xianggen Wu. Nanomicelle formulation for topical delivery of cyclosporine A into the cornea:in vitromechanism andin vivopermeation evaluation. Sci Rep. 2015, 5: 12968.

[13]Yue Zhao¹,Chuanlong Guo¹, Lijun Wang, Shuaiyu Wang, Xiangqian Li, Bo Jiang, Ning Wu, Shuju Guo, Renshuai Zhang, Kun Liu, Dayong Shi. A novel fluorinated thiosemicarbazone derivative- 2-(3,4-difluorobenzylidene) hydrazinecarbothioamide induces apoptosis in human A549 lung cancer cells via ROS-mediated mitochondriadependent pathway. Biochemical and Biophysical Research Communications. 2017, 491:65-71.

[14]Hua Liu¹,Chuanlong Guo¹, Shuju Guo, Lijun Wang, Dayong Shi. Design and Synthesis of a Fluorescent Probe with a Large Stokes Shift for Detecting Thiophenols and Its Application in Water Samples and Living Cells. Molecules. 2019,24, 375.(IF: 3.098)

[15]Guo Chuanlong¹, Wang Lijun¹, Jiang Bo, Shi Dayonng. Bromophenol curcumin analog BCA-5 exerts an antiangiogenic effect through the HIF-1α/VEGF/Akt signaling pathway in human umbilical vein endothelial cells. Anti-Cancer Drugs. 2018, 29(10):965-974.

[16]Chuanlong Guo¹, Lijun Wang¹, Yue Zhao, Bo Jiang, Jiao Luo, Dayong Shi. BOS-93, a novel bromophenol derivative, induces apoptosis and autophagy in human A549 lung cancer cells via PI3K/Akt/mTOR and MAPK signaling pathway. Experimental and Therapeutic Medicine. 2019,17: 3848-3858.

2、授权专利

[1]吴祥根，郭传龙，李梦双，史伟云。一种33G针头注射用雷珠单抗眼玻璃体腔内缓释药物.2019,中国,授权专利号: ZL 201510371614.5

[2]吴祥根，郭传龙，李梦双，史伟云。一种姜黄素胶束滴眼液及其制备方法. 2018,中国,授权专利号: ZL 201510389806.9

[3]吴祥根，郭传龙，李梦双，史伟云。一种姜黄素胶束鼻腔给药用溶液及其制备方法. 2017,中国,授权专利号: ZL 201510391874.9

[4] 史大永，郭传龙，王立军，赵越，江波，李祥乾。一种哌啶-溴酚-吲哚酮杂合体化合物在抗肿瘤药物中的应用。2020,中国,授权专利号: ZL 201810753795.1

[5] 史大永，郭传龙，王立军，赵越，江波，李祥乾。三醛基间苯三酚缩氨基硫脲杂合体化合物在抗肿瘤药物中的应用。2020,中国,授权专利号: ZL 201810753795.1

[6]史大永，王立军，郭传龙，江波，王帅玉，赵越。一类新型溴酚氨基硫脲类化合物及其制备和药物与用途。2019,中国,授权专利号: ZL 201611069927.6

[7]史大永，王立军，郭传龙，李祥乾，江波，李晓伟。六种PARP1抑制剂的制备及其应用。2020,中国,授权专利号: ZL 201810812259.4

►承担的科研项目

[1] 2021.1-2023.12新型小分子化合物靶向调控eIF4E抗肺癌作用及机制研究。山东省自然科学基金青年基金，主持，在研。

[2] 2019.9-2024.8抗肿瘤先导化合物筛选及作用机制研究。青岛科技大学人才启动经费。主持，在研。

[3]2015.7-2016.12姜黄素纳米胶束经鼻腔粘膜-三叉神经节-角膜神经通路治疗糖尿病性角膜病变及其机制研究。山东省自然科学基金，项目编号：ZR2015PH06。主持，已结题。